Results 51 to 60 of about 13,138 (168)
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aim Cardiovascular disease (CVD) is the leading cause of mortality in individuals with diabetes. Diabetic kidney disease, closely related to CVD risk, is prevalent in up to 40% of this population. Emerging evidence suggests ceramide lipids as accurate biomarkers for CVD.
Kristina Pigsborg +10 more
wiley +1 more source
Ocular Manifestations of Metabolic Syndrome: A Systemic Vascular Phenotype
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Context Metabolic syndrome (MetS) is defined by central obesity, insulin resistance, hypertension and dyslipidemia. MetS affects over one‐third of US adults. Beyond its cardiovascular burden, MetS has clinically relevant associations with ocular health and may contribute to a systemic vascular and neuro‐metabolic phenotype involving the retina,
Ron T. Varghese, Ansu A. John
wiley +1 more source
Fenofibrate protects endothelial cells against the harmful effects of TNF-alpha
SA Heart Journal, 2017 Introduction: Fenofibrate exerts pleiotropic effects on endothelial cells (ECs) by, amongst others, increasing nitric oxide (NO) production. We aimed to investigate fenofi brate’s putative beneficial actions in healthy or TNF-alpha-induced dysfunctional ...
Westcott, Corli +6 more
doaj +1 more source
High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy. [PDF]
PLoS ONE, 2011 In a recent FIELD study the fenofibrate therapy surprisingly failed to achieve significant benefit over placebo in the primary endpoint of coronary heart disease events. Increased levels of atherogenic homocysteine were observed in some patients assigned
Laxman Yetukuri +10 more
doaj +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Diabetes mellitus (DM) and chronic kidney disease (CKD) frequently coexist and together create a ‘triple threat’ with dyslipidaemia, enhancing the risk for cardiovascular morbidity and mortality. Diabetic kidney disease (DKD) leads to altered lipid metabolism through insulin resistance, inflammation and oxidative stress resulting in an ...
Ann S. Forrest +3 more
wiley +1 more source
Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou +5 more
wiley +1 more source
Molecular Cancer, 2010 Background Glioblastomas are characterized by rapid cell growth, aggressive CNS infiltration, and are resistant to all known anticancer regimens. Recent studies indicate that fibrates and statins possess anticancer potential.
Del Valle Luis +7 more
doaj +1 more source
Pemafibrate Improves Cholestatic Markers Regardless of the Presence of Primary Biliary Cholangitis
Hepatology Research, EarlyView.Pemafibrate improves liver function markers related to bile flow in primary biliary cholangitis (PBC), but whether this effect is disease‐specific remains unclear. In this study, pemafibrate reduced these markers in patients with and without PBC, suggesting broader effects on bile flow beyond PBC.
Ryohei Tanigawa +5 more
wiley +1 more source
Eruptive Xanthomas in a Patient With Severe Dyslipidemia
JEADV Clinical Practice, EarlyView.
Michał Niedźwiedź +3 more
wiley +1 more source
Internal Medicine Journal, EarlyView.Abstract Background Socio‐economic status (SES) is strongly linked to health outcomes but remains difficult to measure accurately. Conventional approaches based on large geographical units (e.g. postcodes) may obscure SES effects evident at smaller scales.
Andrzej S. Januszewski +8 more
wiley +1 more source